Furthermore, c-di-GMP-activated STING demonstrates promising immunotherapeutic efficacy in breast cancer (Chandra et al., 2014), whereas c-di-GMP-loaded peptide nanotubes enhance immunotherapy for melanoma (Zhang et al., 2022c). This evidence concerns the gene STING1 and breast carcinoma.